Do you want to gain expert insights on the role of kidney biopsy and complement assays for complement-mediated kidney diseases?    Credit available for this activity expires: 4/13/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990635?ecd=bdc_podcast_libsyn_mscpedu

Half of people with severe non-proliferative diabetic retinopathy will have proliferative disease within a year. What can be done?    Credit available for this activity expires: 03/31/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989799?ecd=bdc_podcast_libsyn_mscpedu

Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies? 

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989395?src=mkm_podcast_addon_989395

What is the clinical use of biosimilars and how to best communicate with patients to avoid the nocebo effect? 

Credit available for this activity expires: 3/29/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990193?ecd=bdc_podcast_libsyn_mscpedu

Do you reload when switching? What intervals do you extend by? How long is feasible between treatments, and how do you monitor? Learn from the experts.    Credit available for this activity expires: 28/03/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990120?ecd=bdc_podcast_libsyn_mscpedu

Do you know how study designs influence the data with anti-vascular endothelial growth factor (anti-VEGF) therapies? Find out more. 

Earn Credit / Learning Objectives & Disclosures:  https://www.medscape.org/viewarticle/[ArticleID]?src=mkm_podcast_addon_989801

Did you know that SGLT2 blockade can reduce progression to ESKD by at least a decade in patients with mild-to-moderately decreased eGFR?

Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990093?ecd=bdc_podcast_libsyn_mscpedu

Do you know which you should be treating first -- the systemic mastocytosis (SM) or the associated hematological neoplasm (AHN)?    Credit available for this activity expires: 3/24/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/990024?ecd=bdc_podcast_libsyn_mscpedu

Who should be taking a glucagon-like peptide-1 (GLP-1) receptor agonist (RA)? Join Drs Bain and Lin to find out.

Credit available for this activity expires: 3/23/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989998?ecd=bdc_podcast_libsyn_mscpedu

Do you know the latest information about dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risk? Drs Navar and Ray discuss.    Credit available for this activity expires: 03/21/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/[989864]?ecd=bdc_podcast_libsyn_mscpedu